December 21, 2020 -- Cell therapies firm Legend Biotech has begun a rolling submission of a biologics license application (BLA) to the U.S. Food and Drug Administration (FDA) for a chimeric antigen receptor (CAR) T-cell therapy for adults with myeloma.
The therapy is an investigational B-cell maturation antigen (BCMA)-directed CAR T-cell treatment designed for adults with relapsed and/or refractory multiple myeloma. The BLA was submitted based on promising results from a phase IB/II trial evaluating the therapy's safety and efficacy in patients.
Legend's collaborative partner, Janssen Biotech, submitted the BLA to the FDA, noted Legend. In 2017, Janssen and Legend entered into a global license and collaboration agreement to develop and commercialize cilta-cel.
Under terms of its existing agreement, Legend has achieved a $75 million milestone payment related to the clinical development of cilta-cel and submission of the BLA. The firm will also continue to study the efficacy cilta-cel in the ongoing phase II portion of the open-label, multicenter clinical trial.
Copyright © 2020 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
